Search results
Results from the WOW.Com Content Network
Buspirone, sold under the brand name Buspar among others, is an anxiolytic, a medication primarily used to treat anxiety disorders, particularly generalized anxiety disorder (GAD). [ 10 ] [ 11 ] It is a serotonin 5-HT 1A receptor partial agonist , increasing action at serotonin receptors in the brain. [ 3 ]
Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity. [4] [6] It contains naltrexone, an opioid antagonist, and bupropion, an aminoketone atypical antidepressant. [4]
A 2022 study sponsored by Eli Lilly followed more than 2,500 adults with a BMI of 30 or more and without diabetes. It looked at the effectiveness of tirzepatide for 72 weeks at different doses ...
Keppra (levetiracetam) – an anticonvulsant drug which is sometimes used as a mood stabilizer and has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome, anxiety disorder, and Alzheimer's disease; Klonopin – anti-anxiety and anti-epileptic medication of the benzodiazepine class
For the first time in over a decade, obesity rates in the United States may finally be heading in the right direction and new weight loss drugs like semaglutide could be part of the reason why. A ...
Buspirone (Buspar) – 5-HT 1A receptor partial agonist; Lithium (Eskalith, Lithobid) – mood stabilizer (mechanism of action unknown/unclear) Thyroxine (T 4) – thyroid hormone (thyroid hormone receptor agonist) Triiodothyronine (T 3) – thyroid hormone (thyroid hormone receptor agonist)
A 15-milligram dose of VK2735 helped patients lose up to 14.7% of their body weight on average in the study, which enrolled 176 overweight adults with at least one weight-related comorbidity.
The dose of bupropion in the study was lower than the target dose recommended for clinical practice. [10] In this study, dextromethorphan/bupropion showed significantly greater improvement than bupropion alone in the first two weeks of treatment but not by week 6 of treatment in people with major depressive disorder.